CATX ▲ +6.4% - Perspective Therapeutics, Inc. $CATX - Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-? Positive Solid Tumors Perspective Therapeutics rose 6.4% following its announcement of a clinical collaboration and supply agreement with Merck to evaluate its experimental therapeutic [212Pb]PSV359 alongside Merck's established immunotherapy Keytruda in FAP-positive solid tumors. The partnership with a major pharmaceutical company and the expansion of its asset into combination studies with a leading cancer drug likely drove investor enthusiasm for the company's clinical pipeline. 14-SEP-2026 06:16 AM ET